BRCA2 and metastatic neoplasm: The presence of a germline HRR variant also influences management beyond the PARP setting; for example, some experts favor earlier intensification with docetaxel or potent ARSIs in BRCA2 carriers with high-volume metastatic disease, given their higher risk of early progression on androgen-deprivation therapy alone [17,18,26,30].